Shanghai Pharmaceuticals

SciClone Pharmaceuticals is a specialty pharmaceutical company engaged in the development and commercialization of therapies primarily for oncology, infectious diseases, and cardiovascular disorders. Headquartered in Foster City, California, the company’s lead product, ZADAXIN, is utilized for treating hepatitis B and C, certain cancers, and as an immune system enhancer, with ongoing development aimed at addressing sepsis. In addition to ZADAXIN, SciClone markets various products, including DC Bead, which is approved for liver cancer treatment in multiple countries, and ondansetron RapidFilm for managing nausea and vomiting related to cancer therapies. The company has established strategic partnerships to promote products like Angiomax and Cleviprex. With a focus on addressing unmet medical needs, particularly in the rapidly growing markets of China, SciClone Pharmaceuticals continues to expand its portfolio and enhance its global presence.

CITIC Pharmaceutical Co., Ltd. (中信医药) is a pharmaceutical service provider that supplies medicine and related consumables to hospitals. It is a large pharmaceutical operation enterprise integrating medicines supply to hospitals, cross-regional commercial distribution, vaccine sale, medical instruments and consumables sale, and medicine retailing service. In recent years, it has become a pharmaceutical service provider in the supply chain with multiple customized integration service. CITIC Pharmaceutical, which is a subsidiary of CITIC Group, was transformed to a joint venture in 2007. It is invested by China Health System whose holding company is Bioveda China fund and CITIC Investment Holdings Ltd.